Skip to main content
Premium Trial:

Request an Annual Quote

Ventana, Boehringer Ingelheim to Collaborate on CDx for Cancer Drugs

NEW YORK (GenomeWeb News) – Ventana Medical Systems and Boehringer Ingelheim announced today that they will collaborate on the development of companion diagnostic products for cancer drugs in the German drug firm's pipeline.

Ventana plans to utilize its immunohistochemistry technology platform and its experience in companion diagnostic development and premarket approval submissions to support Boehringer Ingelheim's personalized medicine strategies for cancer drug development, the firms said. The partners didn't name specific drug candidates or types of cancers that would be targeted by the collaboration.

Further terms of the alliance also were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.